XML 29 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information
6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Segment Information
Segment Information
The Company operates as two reportable segments:
The Consumer Operations segment, which reflects the total revenue and costs and expenses related to HOTSHOT and the Company's consumer operations.
The Drug Development segment, which reflects the costs and expenses related to the Company's efforts to develop innovative and proprietary drug products; previously to treat muscle cramps, spasms and spasticity associated with severe neurological conditions.
The Company discloses information about its reportable segments based on the way that the Company's Chief Operating Decision Maker, who the Company has identified as the Chief Executive Officer, and management, organizes segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its reportable segments based on revenue and operating income or loss. Although the Company reduced its research and development efforts in connection with its strategic assessment in June 2018, the Company continues to manage and operate as two segments and it is unclear to what extent it may resume research and development activities in the future. The accounting policies of the segments are the same as those described herein as well as those described in Note 2. Corporate and unallocated amounts that do not relate to a reportable segment have been allocated to "Corporate." No asset information has been provided for the Company's reportable segments as management does not measure or allocate such assets on a reportable segment basis.
Information for the Company's reportable segments for the three months ended June 30, 2019 and 2018 are as follows:
 
Three Months Ended June 30, 2019
Consumer Operations
Drug Development
Corporate
Consolidated
Total revenue
$
164,705



$
164,705

Interest income, net
$


13,361

$
13,361

Income (loss) from operations
$
11,821

(29,294
)
(1,380,665
)
$
(1,398,138
)
Three Months Ended June 30, 2018
Consumer Operations
Drug Development
Corporate
Consolidated
Total revenue
$
245,502



$
245,502

Interest income, net
$


51,809

$
51,809

Loss from operations
$
(645,687
)
(6,170,488
)
(2,287,506
)
$
(9,103,681
)
 

Information for the Company's reportable segments for the six months ended June 30, 2019 and 2018 are as follows:
 
Six Months Ended June 30, 2019
Consumer Operations
Drug Development
Corporate
Consolidated
Total revenue
$
269,682



$
269,682

Interest income, net
$


26,574

$
26,574

Loss from operations
$
(41,287
)
(29,678
)
(3,570,816
)
$
(3,641,781
)
Six Months Ended June 30, 2018
Consumer Operations
Drug Development
Corporate
Consolidated
Total revenue
$
424,084



$
424,084

Interest income, net
$


111,402

$
111,402

Loss from operations
$
(1,902,993
)
(10,834,565
)
(4,648,943
)
$
(17,386,501
)